<DOC>
	<DOCNO>NCT01039974</DOCNO>
	<brief_summary>This study determine effect 400 mg ketoconazole pharmacokinetics single dose GSK962040 . The result study help estimate maximum increase exposure concomitant use strong CYP3A4 inhibitor . This study also contain exploratory investigation biliary secretion GSK962040 metabolites .</brief_summary>
	<brief_title>GSK962040 Drug-drug Interaction Study With Ketoconazole</brief_title>
	<detailed_description />
	<mesh_term>Gastroparesis</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . In case , liver function test must strictly within normal range screening . Male female 18 65 year age inclusive , time signing informed consent . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 MlU/mL estradiol &lt; 40 pg/mL ( &lt; 140 pmol/L ) confirmatory ] . Childbearing potential agrees use one contraception method list Section 8.1 appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception least 5 day follow last dose study medication . GSK962040 ketoconazole define study medication . Male subject must agree use one contraception method list Section 8.1 . This criterion must follow time first dose study medication least 5 day follow last dose study medication . GSK962040 ketoconazole define study medication . Body weight &gt; = 50 kg BMI within range 18.529.9 kg/m2 ( inclusive ) . Capable give write informed consent QTcB QTcF &lt; 450 msec QTc &lt; 480msec subject Bundle Branch Block base single average QTc value triplicate value obtain brief recording period . Normal physical examination ( physical exam demonstrate evidence clinically active disease physical mental impairment ) . A subject clinical abnormality may include Principal Investigator physician designee considers abnormality introduce additional risk factor interfere study procedure . Consultation GSK medical monitor require subject may include . History major gastrointestinal surgical procedure . History cholecystectomy biliary tract disease . A history presence recreational drug abuse dependence current abuse evidence positive prestudy drug/alcohol screen . A minimum list drug screen include amphetamine , barbiturate , cocaine , opiates , cannabinoids benzodiazepine . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . History regular alcohol consumption within 6 month study define : An average weekly intake &gt; 14 drink male &gt; 7 drink female . One drink equivalent 12 g alcohol : 12 ounce ( 360 mL ) beer , 5 ounce ( 150 mL ) wine 1.5 ounce ( 45 mL ) 80 proof distil spirit . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Pregnant female determine positive serum urine hCG test ( first urine day ) screen prior dosing . Lactating pregnant female . Unwillingness inability follow procedure outline protocol . Consumption red wine , seville orange , grapefruit grapefruit juice pummelo , exotic citrus fruit , grapefruit hybrid fruit juices 7 day prior first dose study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>ketoconazole</keyword>
	<keyword>GSK962040</keyword>
	<keyword>Drug-Drug Interaction</keyword>
	<keyword>Phase I</keyword>
</DOC>